Yervoy (ipilimumab; Bristol-Myers Squibb/Ono Pharmaceutical) is an intravenous fully humanized immunoglobulin-G1 monoclonal antibody that targets human cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). CTLA-4 is present on activated T-cells and is a negative regulator of T-cell activation within the immune response. Yervoy was designed to inhibit the activity of CTLA-4, which allows for an active immune response against cancer cells. Attempting to modulate the immune response is a popular strategy in melanoma due to instances of spontaneous regression of tumors in response to immunotherapy.
LIST OF FIGURES
13 Figure 1: Yervoy in melanoma – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Yervoy for melanoma
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Yervoy for melanoma
17 Figure 4: Yervoy sales for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES 6 Table 1: Yervoy drug profile
8 Table 2: Yervoy pivotal trial data in melanoma
12 Table 3: Yervoy ongoing late-phase clinical trials in melanoma
18 Table 4: Yervoy sales for melanoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
20 Table 5: Yervoy patient numbers for melanoma across the US, Japan, and five major EU markets, by country, 2017–26
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726